COMP <GO>
QGEN vs UNH // OPERATING MARGIN
Qiagen N.V. (NYSE) VS. UnitedHealth Group Incorporated (NYSE) • 15-METRIC TALLY: QGEN 7
— UNH 8
▲ OPERATING MARGIN LEADER: QGEN
LAST: $50.22 (-0.24%) • MKT CAP: $10.37B
operating-margins
22.30%
LAST: $406.97 (-0.96%) • MKT CAP: $364.66B
operating-margins
4.82%
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (QGEN VS. UNH)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | QGEN | UNH | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | 62.20% | 88.57% | -26.37 | UNH | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | 8.00% | 11.47% | -3.47 | UNH | /roic <GO> |
| EV/EBITDA & P/E Valuation | 17.6x | 16.4x | +1.15 | UNH | /valuation <GO> |
| Free Cash Flow Yield | 4.37% | 6.48% | -2.11 | UNH | /fcf-yield <GO> |
| Operating Margin ACTIVE | 22.30% | 4.82% | +17.48 | QGEN | /operating-margins <GO> |
| Net Profit Margin | 20.30% | 3.14% | +17.16 | QGEN | /net-margins <GO> |
| Revenue Growth (YoY) | 5.70% | 6.46% | -0.76 | UNH | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.52% | 2.28% | -1.76 | UNH | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | 3.54 | 3.12 | +0.42 | QGEN | /balance-sheet <GO> |
| Piotroski F-Score Quality | 9/9 | 7/9 | +2.00 | QGEN | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | 6.70% | 6.74% | -0.04 | QGEN | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 71.9 | 56.0 | +15.88 | QGEN | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | 0.95 | 0.33 | +0.62 | QGEN | /macro-sensitivity <GO> |
| Forward P/E Multiple | 22.7x | 17.1x | +5.61 | UNH | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $10.37B | $364.66B | -$354.29B | UNH | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | QGEN REV | UNH REV | QGEN GROSS % | UNH GROSS % | QGEN FCF | UNH FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $2.09B | $447.57B | 62.2% | 88.7% | $453.3M | $16.07B |
| FY 2024 | $1.98B | $400.28B | 48.9% | 88.3% | $506.4M | $20.70B |
| FY 2023 | $1.97B | $371.62B | 44.0% | 89.6% | $371.0M | $25.68B |
| FY 2022 | — | $324.16B | — | 89.6% | — | $23.40B |
| FY 2021 | — | $287.60B | — | 89.2% | — | $19.89B |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
QGEN // BETA 0.95
UNH // BETA 0.33